Last week, we celebrated an important CMS policy update: Under a new rule, called Medicare Coverage of Innovative Technology (MCIT), as soon as the FDA approves a new breakthrough technology, Medicare can cover that breakthrough technology. Today, in an op-ed in Morning Consult, AdvaMed President and CEO Scott Whitaker encouraged the Biden administration to work with our industry to implement and strengthen the rule, saying, “Too many seniors’ lives depend on it.”
We recently hosted more than 200 medtech leaders for our second annual Summit on Inclusion & Diversity. Special thanks to the ten industry leaders who joined us to lead these important and impactful discussions! Learn more about our work on inclusion and diversity.
WASHINGTON, D.C. – An op-ed authored by AdvaMed President and CEO Scott Whitaker was published today in Morning Consult on the importance of COVID-19 diagnostic testing and the role AdvaMed’s new national testing supply registry will play in helping the federal and state governments create and manage COVID-19 diagnostic testing strategies.
Behind the scenes, the medical technology industry is working around-the-clock to manufacture the critical supplies providers need to combat the coronavirus. Across the country, manufacturers are adding shifts, ramping up alternative production lines and working overtime to produce personal protective equipment (PPE), ventilators and the diagnostic tests desperately needed on the front lines.
Scott Whitaker, AdvaMed’s President & CEO, recently joined host David Westin on Bloomberg Radio’s “Balance of Power” program to provide a national audience with an update on how the medical technology industry has mobilized to combat the COVID-19 pandemic.